SAG
IPHA

SageView Advisory Group’s Innate Pharma IPHA Stock Holding History

SageView Advisory Group’s Portfolio IPHA Stock Details IPHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2 Buy
+1
New +$2 ﹤0.01% 2607

Other funds holding IPHA

Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OMC
Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

SageView Advisory Group's IPHA Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Innate Pharma (IPHA) in Q4 2025: 1 share worth $2. The stake represents ﹤0.01% of the portfolio and ranks #2607 among its holdings.

11 funds tracked by Wall St. Rank hold IPHA as of Q4 2025.

  • SageView Advisory Group held 1 share of Innate Pharma worth $2 as of Q4 2025.
  • Innate Pharma was a new SageView Advisory Group position in Q4 2025.
  • Innate Pharma made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #2607 holding.
  • 11 funds tracked by Wall St. Rank held Innate Pharma as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.